

IP LICENSING & COMMERCIALISATION

CARDIMODE®

A Holistic Approach to Heart Health - Antioxidant Herbal Composition

PCT No.: WO2013021302A1

www.iiprd.com www.khuranaandkhurana.com

For more details click below:

www.iiprd.com/ip-licensing-services/

CONTENTS

01 02
LITERATURE ABOUT CARDIMODE

ADOUT CARDIMODE

& ITS ROLE THEREOF

03

MARKET OPPORTUNITY

WHY CARDIMODE

04


® CLIN

CLINICAL DATA & DOSES REGIME

05

LITERATURE: UNDERSTANDING HEART ATTACK

- A heart attack, or myocardial infarction, occurs when a blood vessel supplying the heart muscle is suddenly blocked by a blood clot. This blockage typically arises from the accumulation of cholesterol and other fatty substances within the blood vessel, forming plaque. Over time, plaque buildup narrows and hardens the arteries, a condition known as atherosclerosis. Reduced blood flow to the heart can lead to symptoms such as chest pain (angina) and, if left untreated, permanent damage to the heart muscle.
- Heart is vulnerable to a myriad of risk factors that contribute to heart disease. These include smoking, high cholesterol, high blood pressure, diabetes, obesity, and a sedentary lifestyle, collectively posing a significant threat to cardiovascular health. Plaque accumulation in the arteries, often triggered by elevated cholesterol levels and other risk factors, can culminate in partial or complete blockages, precipitating heart attacks. Additional risk factors encompass genetic predisposition, metabolic syndrome, heavy alcohol consumption, stress, sleep apnea, and certain medical conditions like preeclampsia. Embracing a healthy lifestyle, characterized by regular exercise, a balanced diet, smoking cessation, and effective stress management, is imperative in averting heart disease and mitigating the likelihood of heart attacks.



ABOUT HEART ATTACK & STATISTICS:

- The adult human heart is about the size of a clenched fist.
- Hearts have been known to pump for 100 years without resting more that a second at a time a feat unequaled by any manmade device.
- The average heart beats 60 times a minute; 3,600 times an hour; 86,400 per day; 31.5 million per year, and 2.4 billion in a lifetime.
- In an average lifetime, the heart pumps 1 million barrels of blood enough blood to fill 3.3 supertankers and expends more than enough energy enough to lift a battleship out of the water.
- In the U.S., about 26.3 million men (27.6 percent) and 22.7 million women (22.1 percent) are smokers, putting them at increased risk for a heart attack.
- About 99.5 million American adults have total blood cholesterol values of 200 mg/dL and higher (borderline high). About 39.9 million American adults have total blood cholesterol levels of 240 or above (high). An elevated blood cholesterol level is a risk factor for a heart attack.
- As many as 50 million Americans have high blood pressure, which places them at risk for a heart attack.
- About every 29 seconds, an American will experience a heart problem.
- It's estimated that 7.2 million Americans age 20 and older have a history of a heart attack (4.4 million men and 2.8 million women).
- Each year, about 1.1 million Americans are expected to have a new or recurrent coronary attack.

MAJOR & POTENTIAL RISKS

Anything that damages the inner layers of your coronary arteries can lead to plaque buildup, artery blockage and heart disease, according to the National Heart Lung and Blood Institute, or NHLBI. Apart from high cholesterol levels, known major risk factors for this type of damage include high blood pressure, abnormal resistance to the effects of a hormone called insulin, smoking, lack of exercise or physical activity, diabetes, smoking, advancing age, being overweight or obese and consumption of an unhealthy diet.

Another major risk factor, called metabolic syndrome, arises when you simultaneously have several other heart disease risks. Some people also have a genetic predisposition toward coronary heart disease that creates a major risk apart from any additional factors. Men typically have higher heart disease risks than women.

Certain other factors may also increase your coronary heart disease risks, the NHLBI reports. They include heavy alcohol consumption, stress, the presence of a condition called sleep apnea, high blood levels of a fatty substance called triglycerides and the presence of a pregnancy-related condition called preeclampsia. You may also have an increased risk for atherosclerosis in your coronary arteries if you have a history of artery-related problems such as an aortic aneurysm or a stroke.

ABOUT CARDIMODE® & IT'S ROLE THEREOF

ABOUT

CARDIMODE®, a proprietary herbal medicine protected by patent, offers a promising solution for managing cholesterol levels and promoting heart health. With its natural formulation and proven efficacy, CARDIMODE® serves as an effective supplement for individuals looking to improve their cardiovascular well-being.

- CARDIMODE® is clinically indicated for removing bad cholesterol deposits and strengthening heart function.
- Its composition includes Terminalia arjuna, Camellia sinensis, and TRIKATU, each contributing to its therapeutic benefits.
- The recommended dosage regimen ensures optimal therapeutic effects, with dosing instructions tailored to adults and children, under the guidance of a registered medical practitioner.

ROLE


Cholesterol Regulation: CARDIMODE regulates cholesterol metabolism, reducing LDL (bad) cholesterol and promoting HDL (good) cholesterol levels with natural ingredients like Terminalia arjuna, Camellia sinensis, and TRIKATU.

Cardiovascular Support: By enhancing blood flow, reducing plaque buildup, and strengthening heart function, CARDIMODE supports overall cardiovascular health, reducing the risk of heart attacks and strokes.

Anti-inflammatory and Antioxidant Effects: CARDIMODE's potent anti-inflammatory and antioxidant properties combat oxidative stress and inflammation, protecting against endothelial dysfunction and arterial damage.

Prophylactic and Therapeutic Use: Suitable for both preventive and therapeutic purposes, CARDIMODE serves as a proactive measure for maintaining heart health and managing cardiovascular risk factors.

CARDIMODE FEATURES:



THERAPEUTIC STATUS:

LABORATORY AND ANALYTICAL INFORMATION:

- $1.\,Crude\,Drug/Plant\,collected\,from\,the\,origin$
- 2. Standard logistic utilized
- 3. Separating part to be used and washed with warm water.
- 4. Drying the material
- 5. Plant part/Material granulated as required and sieved to the necessary size partial
- 6. Shifted for soaking Solubility substance.
- 7. Air Conditioning & Dehumidifier installed and temperature maintained as required for the process.

PHYSICAL APPEARANCE OF THE EXTRACT:

- SolubilitypH 1 %w/v soln.
- pri i 70w/ v som
- Ash Content
- Loss on Drying
- Heavy Metals

MICRO BIOLOGICAL:

- Total Plate Count
- Total Yeast & Mould
- E.Coli
- Salmonella
- S.aereus

SAFETY & TOXICITY TEST: LD50 Done on both genders STABILITY TEST: Compliance provided by Extract manufacturer

MARKET OPPORTUNITY

INDUSTRY OVER VIEW

- India is the world's largest exporter of generic drugs, making almost 40% of all new generic the FDA approved in 2018 through October.
- Overall, cardiovascular diseases contributed 28·1% (95% UI 26·5–29·1) of the total deaths and 14·1% (12·9–15·3) of the total DALYs in India in 2016, compared with 15·2% (13·7–16·2) and 6·9% (6·3–7·4), respectively, in 1990

ESTIMATION OF MARKET


- This market is estimated to grow at CAGR of 4.9%
- The estimated market was \$19.2bn in 2017.
- In the statins and fixed dose combination segment, Crestor was on the leas dub 2016 and held a share of 26.7%.
- It has been forecasted that it would grow to \$23billion by 2021.

INVESTMENT OPPORTUNITY

- The idea behind is that it wants to create social impact.
- It aims to help people by providing with high quality medicine.
- It aims to help people by providing with affordability.
- These medicines are made from herbal and/or plants extracts.
- It is based on new advanced technology.
- Nowadays, people are prone to the usage of allopathic medicine despite of they having multiple side effects. This are biotech products which minimize the range of side effects and are beneficial to cure severe diseases like malaria, Liver dysfunction and Cholesterol.

MARKET OPPORTUNITY


- India is the largest provider of generic drugs globally. It contributes to over 50% of global demand for various vaccines.
- The India pharmaceutical market size reached US\$ 54.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 163.1 Billion by 2032.
- This has been expected to expand at a CAGR of 12.3%
- India's domestic pharmaceutical market turnover reached Rs. 4100 crore (US\$ 41 Billion), growing at 9.8% YOY growth.
- India's biotechnology industry comprising bio-pharmaceuticals, bio-services, bio-agriculture, bio-industry and bioinformatics is expected grow at an average growth rate of around 30 per cent a year and reach US\$ 100 billion by 2025



MARKET OPPORTUNITY: STATISTICS

HEART DISEASE IS THE BIGGEST KILLER

Many more people die of heart disease than cancer. In 1990, cardiovascular diseases accounted for 15.2% of all deaths; by 2016, this shot up to 28.1% with 2.8 million dying of heart problems. But, again, if you look at the age-standardised rate, there is no significant change in the 26-year period





224.4

per 100,000

The age-adjusted US death rate attributable to CVD (build on 2020 data)



239.8 per 100,000

The age-adjusted global death rate attributable to CVD (based on 2020 data)



on average, someone in the US dies of CVD every 34 seconds

2544 US deaths from CVD each day (based on 2020 data)



dies of a stroke every

3 minutes and 17 seconds

439 US deaths from stroke each day (based on 2020 data)

WHY CARDIMODE ?

CARDIMODE® stands out as a beacon of hope in the realm of cardiovascular health, offering a compelling solution backed by science and nature. With its unique blend of botanical ingredients, including Terminalia arjuna, Camellia sinensis, and TRIKATU, this proprietary herbal medicine presents a promising avenue for individuals seeking to manage their cholesterol levels and safeguard their heart health. Unlike synthetic alternatives, CARDIMODE® embraces the power of nature, harnessing the therapeutic properties of these plants to deliver tangible benefits to its users.

One compelling reason to consider CARDIMODE® is its proven efficacy in regulating cholesterol levels and promoting cardiovascular well-being. Through its targeted action on LDL (bad) cholesterol reduction and HDL (good) cholesterol elevation, this herbal supplement offers a holistic approach to cholesterol management, addressing a key risk factor for heart disease. Moreover, CARDIMODE® not only focuses on symptom management but also targets the root causes of cardiovascular dysfunction, providing a comprehensive solution for those looking to proactively enhance their heart health.

Furthermore, CARDIMODE® stands as a beacon of safety and reliability in the realm of natural supplements. With a carefully crafted formulation and rigorous clinical testing, this herbal medicine offers peace of mind to consumers, ensuring both efficacy and safety. Whether used as a preventive measure or as part of a therapeutic regimen, CARDIMODE® emerges as a compelling choice for individuals seeking to prioritize their cardiovascular health and embark on a journey towards vitality and longevity.

EXEMPLARY CLINICAL DATA - PART-I: Before consuming

PILOT CASE STUDY - LIPUS™ 500 mg.Each Hard gelatin Capsule- Colour Code:BROWN- As per FDA Specification HERBAL COMPOSITION FOR THE TREATMENT OF LIPOPROTEIN AND CLINICAL OBSERVATION DATA

Exhibit: A

Sr. No.	Pateint Name	Male/Fe male Age :f/M	Date of Test	Symptoms	Wt. on date of test (in Kg.)	Medication (Conventional Drug)	Duration of course of conventional drug	Side / Adverse Effect of conventional drug	Wt. after medication with convention al drug	Conclusion of conventional drug	LIPUS TM Dosage Regime	Herbal composition provied on and duration		Other medications, #F ANY.	Side / Adversa Effect ,IF ANN
_	Vilasben N.Oevani	45/F	3/1/2011	High Choic-	51	None	N/A	N/A	N/A	N/A	2 X 2 b.i.d.	3/1/2011	55	None	NII.
	* Hayber 14,Dexons	2200	37.1.22.1	sterol,Chest-	1					- 2017	4057	3 Months			
	A. 1891		1988	pain, High-											2000
				Triglyceride											
_	Mark the 18 of t	52/M	3/2/2011	M.I. High BP,	69	Ecosprin-	One Year	Tiredness	65	Tiredness	2x2b.i.d.	3/2/2011	72	None	Nii
- 2	Vitthalbhai Savaliya	52/M	3/2/2011	will, right or,	02	1-1 a day	One real	Bodyache		1460-1640	2.0.2	3 Months			
		+				Sorbitrate-		COCYDENC			***				1457
						1-1 a day				**	(10X)	0			
								447			242514	3/3/2011	62	None	NII.
3	Raben Sorathiya	40/F	3/3/2011	High BP.	65	Asperin-	2 Months	Nil	50	N/A	2 X 2 b.i.d.	3 Months	02	HOME	No.
-		-		Cholesteral,		1-1 a day			1 1	-3 - 3	_	2 talibutes			
	(a)	-		Chest Pain,	-1	Sorbitrate-			 		- 3				
		+		Triglyceride	\vdash	1 a day		-					-		-
4	Jayaben V.Bhuha	48/4	3/4/2011	High Choie-	62	Altace:1 X 1	2 Years	Sedation,	60	N/A	2 X 2 b.i.d.	3/4/2011	63	None	Nd.
				sterol,		Ecosprin-	1	Tiredness	1000			3 Months			
		1		Triglyceride,		1 X 1 a day		4		\$ 800KG					
**			-0.00	Anxiety, BP,		Sorbitrate-			1000				100		
				Heart Attack.		1 X La day									
-	Ramilaben KJadav	45/F	3/5/2011	High Chole-	58	None	New-	N/A	N/A	N/A	2X2bid.	3/5/2011	65	None	Nsl.
. 3	Kamilaben Kuabay	43/1	मुज्ञस्ता	sterol.	+~	10000	Case				A 40000	3 Months			
		+		Anxiety,		1970	1 "	g 7 - W							
-	7500000 75000000		97.40	Chest pain,											
_				Arms pain,							nach.				-
				Bradycaria				900 0000000		80.00	22				9551

EXEMPLARY CLINICAL DATA - PART-II: Before Consuming

26 Ramilaben Vagtushiya	40/7	4/25/2011	Triglyceride,	74	Langxin	5 Months	Uneasiness	73	N/A	2 X 2 a day	4/25/2011	79	Only Glucobay for diabetes - and LIPUS	NIL
			LDL.		1 X 1 a day.						3 Months			
			Diabetes		Ecosprin-									
				7	1 X 1 a day.									
					Glucobay-									
					1 X 1 a day,									
27 Dilipbhai Vaghani	39/M	4/25/2011	LDL,	80	N/A.	New Case	Obeisity,	80	Uneasiness	2 X 2 a day	4/26/2011	80	None	NIL
			Triglyceride				Tiredness,				3 Months		LIPUS Only.	
							Sweating							
28 Ghanshyambhai Shaxi	57/M	4/27/2011	LDL	65	Asairin-	5 Months	Tiredness	63	Tiredness	2 X 2 a day	4/27/2011	69	None	NIL
Kol-Guanarikarinanan ariam	20,100	4/2//2021	Trigiyceride		1X1aday,	B.1116/14/15	THERMAL		CHARLES .		3 Months		Only LIPUS	7100
-			91		Sorbitrate-									
					1 X 1 a day,									
					Isoprel-									
					1 X 1 a day,									
29 Labhuben Patel	65/F	4/28/2011	LDL	80	Dispirin-	2 Months	Obeise.	80	Tiredness	2 X 2 a day	4/28/2011	85	None	NIL
			Triglyceride		1 X 1 a day	-	Tiredness				3 Months		Only LIPUS	
													Isordil 1 a	
30 Pravin Luhar	45/M	4/30/2011	LDL, BP,	75	Isordii-	1 Month	Tiredness	72	Tiredness	2 X 2 a day	4/30/2011	79	day and LIPUS	Nause
			Occassional-		1 a day,						3 Months			
			Trachycardia		Aspirin-						(0.00			
					1X1a day									

Physician's Comments: The volviuntary Clinical Trials of above patients had been observed and undertaken by me and provided free herbal drug named: "LIPUS". The clinical observation for three months suggests further duration of course to accurre more prolific results. I would definitely suggest the outstanding research drug "LIPUS" which has fetched results with safety and efficacy and further without any interaction even if taken with the conventional drug. The novel composition has pathophysiological significance with safety and efficacy as observed by me.

EXEMPLARY CLINICAL DATA - PART-I: After Consuming

PILOT CASE STUDY - LIPUS™ 500 mg.Each Hard gelatin Capsule- Colour Code:BROWN- As per FDA Specification HERBAL COMPOSITION FOR THE TREATMENT OF LIPOPROTEIN AND CLINICAL OBSERVATION DATA Duration of Course - 3 Months

Exhibit: B

No.	Patient Name	Test Report Date Before LIPUS CourseTest /Report Date(After duration of Course)	S.Cholesterol	HDLChole.	CH/HD	S. Triglyceride	V.L.D.L.	LDL	LD/HD (Ratio)
1	Vilasben N.Devani :F/	/45 3/1/2011					12.9	130.5	
		6/2/2011	216.3	80	207	201.7	8.98	146.2	1.82
2	Vithalbhai savaliya :M.	V52 3/2/2011	1 226.9	63.2	3.6	227.6	30.1	156	2.47
		6/1/2011	1 178	48.7			40.37	165.76	
3	Ilaben Sorathiya ;F/4	40 3/3/2011	1 226.2	64.5	3.5	149	30.2	160.2	2.4
		6/2/2011					2.8	146.2	
4	Jayaben V.Bhuha :F/	/48 3/4/2011	236.3	40.56	5.8	156.2	30	151.2	
		6/4/2011	1 167.4	80.4	2.1	137,5	28.6	137,2	1.7
5	Ramilaben K.Jadav :F/	745 3/5/2011	1 249.1	88.2	2.83	121	23	136	
		6/4/2011	1 229.6	70.6	3.3	156	25.2	151	2.1
6	Bhavnaben K.Patel :F/	/39 3/5/2011	1 268	74			29	151	2.0
		6/6/2011	1 216.3	81.2	2.7	117.3	24.2	132	1.6
7	Pradipbhai L.Patel :M/	/38 3/6/2011	1 248	56	4.43	170	32.8	120	2.1
		6/8/2011	1 206	56	3.68	164	32.8	117.2	2.0
8	Prakashbhai Dobariya :M	/33 3/6/2011					13.4	155.4	
		6/7/2011	1 174.8	47.6	3.67	80.3	16.06	111.2	2.3

Blake

EXEMPLARY CLINICAL DATA - PART-II: After Consuming

21 Banubhai	S.Patel :M/45	3/28/2011	246.5	42.02	5.86	93.5	18.7	185.7	3.7
		6/30/2011	227.8	43.06	5.03	92	17.3	167.02	3.88
22 Himatbha	i Sorathiya :M/47	4/22/2011	239.5	43.6	5.5	156.2	30.8	158.9	3.6
		7/22/2011	212.2	50.6	4.2	139.5	36.5	120.9	2.4
23 Ramanan	ndsingh Rajput :M/58	4/22/2011	227	44.06	5.1	141.8	19.04	130	2.95
		7/21/2011	140.7	45.04	3.12	129.2	18	126	2.8
24 Shardabe	n Shah :F/50	4/21/2011	258.56	40.3	6.4	161.5	29.1	152	3.77
		7/26/2011	217.6	50.8	4.3	141.4	28.3	138.5	2.73
25 Shardabe	n G.Shaxi :F/50	4/24/2011	246.1	44.05	5.6	147.4	28.2	141.2	3.2
		7/26/2011	217.6	50.08	4.3	141.4	28.3	138.5	2.77
26 Ramilabe	n Vaghashiya :F/40	4/25/2011	248	71	3.5	169.7	33.1	155.3	2.19
		7/30/2011	223	78	2.9	166	30.2	149	1.91
27 Dilipbhai	Vaghani :M/39	4/26/2011	223	41.4	5.4	197.3	30.2	156	3.8
		7/27/2011	169.9	48.7	3.5	187.1	37.42	83.78	1.72
28 Ghanshya	ambhai Shaxi :M/57	4/27/2011	234.4	45.06	5.2	153.8	26.2	145.2	3.23
		7/26/2011	226.23	48.9	4.6	153	21.2	120.2	2.45
29 Labhuber	Patel :F/65	4/28/2011	235.4	62.7	3.8	137	31	147.2	2.35
		7/30/2011	196.8	52.2	3.8	152	31.06	156.1	2.99
30 Pravin Lu	har :M/46	4/30/2011	231.5	53.2	4.35	211.9	31.76	71.74	1.35
		7/30/2011	222	51.8	4.2	138	21.17	68.74	1.33

PHYSICIAN'S COMMENT: The clinical trial of above patients with novel composition named "LIPUS" had been observed and taken by me.My review suggest that the patients should continue the aforesaid novel drug for more tenure to obtain prolific results. The drug is safe and has significant efficacy even in case of diabetis mallitus.

DOSES REGIME & PRECAUTIONS



DOSAGE

Adults: Each capsule contains 500 mg of CARDIMODE®. For adults, the recommended dosage is 2 capsules twice daily (b.i.d.), to be taken with water. This regimen is designed to ensure optimal efficacy in managing cholesterol levels and promoting heart health.

Elderly: Similarly, elderly individuals are advised to take 2 capsules of CARDIMODE® twice daily, each containing 500 mg of the supplement. It is important to follow this regimen with water to facilitate easy digestion and absorption.



CONTRAINDICATION/PRECAUTION

- · Alcoholic Drinks to be avoided
- Storage: To maintain potency and efficacy, store CARDIMODE® in a cool and dry place, away from direct sunlight and moisture. Proper storage conditions contribute to the longevity and effectiveness of the supplement.
- Shelf Life: When stored correctly, unopened containers of CARDIMODE® have a shelf life of 20 months. Once opened, the shelf life is reduced to 18 months. Adhering to these storage guidelines ensures the freshness and quality of the product throughout its recommended usage period.



CONTACT US:

www.iiprd.com www.khuranaandkhurana.com



licensing@iiprd.com



0120-4909201



S-378, Panchsheel Park, New Delhi - 110017



INTERNATIONAL OFFICES:

Thailand Office

Level 29, The offices at Central World 999/9 Rama Road, Patham Wan, Bangkok, Thailand10330

Malaysia Office

A-5-10 Empire Tower, SS16/1 Subang Jaya, 47500 Selangor, Malaysia

Nepal Office

8th Floor, Trade Tower, GPO 24668, Thapathali, Kathmandu, 4460 0, Nepal

Vietnam Office

29 Truong Han Sieu Str, HaonKiem District, PO Box: 412, Hanoi, Vietnam

Indonesia Office

Graha Intermasa 3rd Floor JI. Cempaka Putih Raya No.102, Jakarta 10510, Indonesia

US OFFICE:

1755 Eye Street NW, Washington DC 20006 (P)TEL; +1- (202) 970-1340; FAX: +1- (202) 970-1341

UAE/GCC OFFICE

First Choice Business Center, AL-Hudaiba Awards Building, Block A, Dubai, UAE

BANGLADESH OFFICE

30/3 B C Das Street, Lalbagh, Dhaka1205, Bangladesh

SRI LANKA OFFICE

Level 35, West Tower World Trade Center, Colombo 00100, Sri Lanka

MYANMAR OFFICE

119/121, 4TH Floor, Latha Street, Latha Township, Yangon, Myanmar

